Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/13420
標題: 內分泌受器表現於母犬惡性乳腺腫瘤之預後潛力
Prognostic Potential of Hormonal Receptors Expression in Bitches with Malignant Mammary Tumors
作者: 蔡旻烜
Tsai, Min-Hsuan
關鍵字: hormonal receptor;內分泌受器;mammary tumor;dog;immunohistochemistry;乳腺腫瘤;犬;免疫組織化學
出版社: 獸醫學系暨研究所
引用: Ahern TE, Bird RC, Allison E, Bird AE, Wolfe LG. Expression of the oncogene c-erbB2 in canine mammary cancers and tumor-derived cell lines. Am J Vet Res. 57: 693-696, 1996. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11: 155-168. Anderson AC, Simpson ME. The genital system during maturity and senescence. In: Los Altos CA ed. The ovary and reproductive cycle of the dog (Beagle). Geron-X. 195, 1973. Anderson WF, Chatterjee N, Ershler WB, Brawley O. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat. 76: 27-36, 2002. Arafah BM, Finegan HM, Roe J, Manni A, Pearson OH. Hormone dependency in N-nitrosomethylurea- induced rat mammary tumors. Endocrinology. 111: 584-588, 1982. Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Lowik CW, Pols HA, van Leeuwen JP. Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology. 138: 5067-5070, 1997. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ. Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology. 146: 3577-3588, 2005. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer. 79: 1564-1571, 1999. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer database. J Clin Oncol. 21; 1973-1979, 2003. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 19: 1865-1878, 2001. Brodey RS, Goldschmidt MA, Roszel JR. Canine mammary gland neoplasms. J Am Anim Hosp Assoc. 19: 61-90, 1983. Carter SL, Negrini M, Baffa R, Gillum DR, Rosenberg AL, Schwartz GF, Croce CM. Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res. 54: 6270-6274, 1994. Casey HW, Giles RC, Kwapiem RP. Mammary neoplasia in animals. Pathologic aspects and the effect of contraceptive steroids. Recent Res Cancer Res. 66: 129-160, 1979. Chang SC, Chang CC, Chang TJ, Wang ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). J Am Vet Med Assoc. 227: 1625-1629, 2005. Chu LL, Rutteman GR, Kong MC, Kong JM, Ghahremani M, Schmeing M, Misdorp W, van Garderen E, Pelletier J. Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer ResTreat. 50: 11-25, 1998. Colar Z, Ehrmann J Jr, Duskova. Immunohistochemical analysis of the functional status of estrogen receptor cascade in breast cancer. Neoplasma. 45: 83-87, 1998. Coradini D, Daidone MG. Biomolecular prognostic factors in breast cancer. Current Opinion in Obstetrics and Gynecology. 16: 49-55, 2004. Couse JF, Hewwitt SC, Bunch DO, Sar M, Walker VR, Davis BJ, Korach KS. Postnatal sex reversal of the ovaries in mice lacking estrogen receptors α and β. Science. 286: 2328-2381, 1999. Donnay I, Rauis J, Devleeschouwer N, Wouters-Ballman P, Leclerg G, Verstergen J. Comparison of estrogen and progesterone receptor expression in normal and tumor mammary tissues from dogs. Am J Vet Res. 56: 1188-1194, 1995. Dorn CR, Taylor DON, Frye FL, Hibbard HH. Survey of animal neoplasms in Alameda and Contra Costa Counties, California I. Methodology and description of cases. J Natl Cancer Inst. 40: 295-305, 1968. El Etreby MF, Muller-Peddinghaus R, Bhargava AC, Fath El Bar, MR, Graf KJ, Trautwein G.. The role of the pituitary gland in spontaneous canine mammary carcinogenesis. Vet Pathol. 17: 2-16, 1980. Else RW, Hannant D. Some epidemiological aspects of mammary neoplasia in the bitch. Vet Rec. 194: 296-304, 1979. Elston CW, Ellis IO. Pathological prognostic factors in breast cancr. I. The value histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol. 19: 403-410, 1991. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz, Fried G, Nordenskjold M, Gustafsson JA. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 82: 4258-4265, 1997. Fuqua SA, Fitzgerald SD, Chamness GC. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 51: 105-109, 1991. Fugua SA. Estrogen and progesterone receptors and breast cancer. In: Disease of the breast. Harris JR, Lippman ME, Morrow M, Hellman S eds. Lippincott-Raven Publishers, Philadelphia. 261-270, 1996. Gillbertson SR, Kurzman ID, Zachrau RE. Canine mammary epithelial neoplasms: Biological implications of morphologic characteristics assessed in 232 dogs. Vet Pathol. 20: 127-142, 1983. Graham JC, O'Keefe DA, Gelberg HB. Immunohistochemical assay for detecting estrogen receptors in canine mammary tumors. Am J Vet Res. 60: 627-630, 1999. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002; 346 : 340-352. Hampton GM, Mannermaa A, Winquist R, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee WK, Evans GA. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res. 54: 4586-4589, 1994 Harvey HJ. Mammary gland. In Gray S, ed. Current techniques in small animal surgery 4th. Williams & Wilkins Co, Pennsylvania, 579-584, 1998. Hellman E, Lindgren A, Linell F, Mattson P, Nilsson A. Comparison of histology and clinical variables to DNA ploidy in canine mammary tumors. Vet Pathol. 35: 219-226, 1988. Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K, Lindgren A. Prognostic factors in canine mammary tumors: A multivariate study of 202 consecutive cases. Vet Pathol. 30: 20-27, 1993. Hellmen E. The pathogenesis of canine mammary tumours. Cancer J. 9: 282-286, 1996. Horwitz KB, McGuire WL. Specific progesterone receptors in human breast cancer. Steroids. 25: 497-505, 1975. Hu YFH, Lau KM, Ho S-M, Russo J. Increased expression of estrogen receptor β in chemically transformed human breast epithelial cells. Inatl J Oncol. 12: 1225-1228, 1998. Inaba T, Takahashi N, Matsuda H, Imori T. Esrogen and progesterone receptors and progesterone metabolism in canine mammary tumours. Jpn J Vet Sci. 46: 797-803, 1984. Jarvinen TAH, Pelto-Huikko M, Isola J. Estrogen receptor beta is coexpressed with Eralpha andn PR and with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 156: 29-35, 2000. Jonat W. Fist clinical results of antiprogestational treatment with onapristone. Symposium on “Antiprogestins, a new strategy in endocrine cancer therapy”, 21 Annul Meeting of the German Cancer Society, Hamburg, March 7-11, 1994. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A. Histilogical grading and prognosis in dogs with mammary carcinomas: application of human grading method. J Comp Pathol. 133: 246-252, 2005. Kitchell BE, Fidel JL. Tamoxifen as a potential therapy for canine mammary carcinoma. Proc Vet Cancer Soc. 91, 1992. Klijn JGM, De Jong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ, Alexieva-Figusch J. Antiprogestins: a new form of endocrine therapy for breast cancer. Cancer Res. 49: 2851-2856, 1989. Klijn JGM, Setyono-Han B, Sander HJ. Pre-clinical and clinical treatment of breast cancer wih antiprogestins. Human Reprod. 9: 181-189, 1994. Knowlden JM, Gee JMW, Robertson JFR, Ellis IO, Nichoson RI. Int J Cancer. 89: 209-212, 2000. Kommoss F, Pfisterer J, Idris T, Giese E, Sauerbrie W, Schafer W. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol. 16: 203-210, 1994. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotype of mouse lacking estrogen receptor beta. Proc Natl Acad Sci USA. 95: 15677-15682, 1998. Kuiper GG, Enmark E, Pelto-Hukko M, Nilsson S, Gustafsson S. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. PNAS. 93: 5925-5930, 1996. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138: 863-870, 1997. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Sagg PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology. 139: 4252-4263, 1998; Kuzmam ID, Gilbertson SR. Prognostic factors in canine mammary tumors. Semin Vet Med Surg. 1: 25-32, 1986. Lengenbach A, Anderson MA, Dambach DM, Sorenmo KU, Shofer FD. Extraskeletal osteosarcomas in dogs: a retrospective study of 169 cases (1986-1996). J Am Anim Hosp Assoc. 34: 113-120, 1998. Lindner V, Kim SK, Karas RH, Kuiper GG, Gustafsson JA, Mendelsohn ME. Increased expression of estrogen receptor-β mRNA in male blood vessels after vascular injury. Circ Res. 83: 224-229, 1998. Locker GY. Hormonal therapy of breast cancer. Cancer Treat Rev. 24: 221-240, 1998. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA. 90: 11162-11166, 1993. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 9: 2266-2278, 1995. Lydon JP, Sivaraman L, Conneely OM. A reappraisal of progesterone action in the mammary gland. J Mammary Gland Biol Neoplasia. 5: 325-338, 2000. MacGuire WL.Steroid receptors in human breast cancer. Cancer Res. 38:4289-4291, 1978. MacGuire WL, Chamness GC, Fuqua SA. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 5: 1571-1577, 1991. Mason JT, O'Leary TJ. Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation. J Histochem Cytochem. 39: 225-239, 1991. Martin de las Mulas J, Ordas J, Millan MY, De Lara M, Espinosa de los Monteros A, Reymundo C, Jover A. Immunohistochemical expression of estrogen receptor β in normal and tumoral canine mammary glands. Vet Pathol. 41: 269-272, 2004. Martin de las Mulas J, Millan Y, Dios R. A prospective analysis of immunohistochemically determined estrogen receptor α and progesterone expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol. 42: 200-212, 2005. Martin PM, Cortad M, Mialot JP. Animal models for hormone-dependent human breast cancer. Cancer Chemother Pharmacol. 2: 13-17, 1984. Mattei MG, Krust A, Stropp U, Mattei JF, Chambon P. Assignment of the human progesterone receptor to the q22 band of chromosome 11. Hum Genet. 78: 96-97, 1988. Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Pli A. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Science. 79: 225-232, 2005. Misdorp W, Cotchin E, Hampe JF, Jabara AG, Von Sandersleben J. Canine malignant mammary tumours. 3. Special types of carcinomas, malignant mixed tumors. Vet Pathol. 10: 241-256, 1973. Misdorp W, Hart AA. Prognostic factors in canine mammary cancer. J Natl Cancer Inst. 56: 779-786, 1976. Misdorp W, Hart AA. Canine mammary cancerI. Prognosis II. Therapy and causes of death. J Small Anim Pract. 20: 385-394, 1979. Misdorp W. Canine mammary tumours: Protective effect of late ovariectomy and stimulating effect of progestins. Vet Q. 10: 26-33, 1988. Misdorp W, Else R, Hellmen E, Lipscomp T. Histological Classfication of Mammary Tumors of the Dog and the Cat. World Health Organization International Histological Classification of Tumors of Domestic Animals. 2nd series, Vol. 7, no. 2. Armed Forces Institute of Pathology, Washington, D.C., 1999. Misdorp W. Tumors of the mammary gland. In: Meuten DJ ed. Tumors in domestic animals 4th ed. Blackwell publishing Co. Iowa State Press, 575-606, 2002. Moe L. Population-based incidence of mammary tumours in some dogs. J Reprod Fertil Suppl. 57: 439-443, 2001. Morris JS, Dobson JM, Bostock DE. Use of tamoxifen in the control of mammary neoplasia. Vet Rec. 133: 539-542, 1993. Morris JS, Dobson JM, Bostock DE, O'Farrell E. Effect of ovariohysterectomy in bitc hes with mammary neoplasms. Vet Rec. 142: 656-658, 1998. Moulton JE, Rosenblatt LS, Goldman M. Mammary tumors in a colony of beagle dogs. Vet Pathol. 23: 741-749, 1986. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science. 289: 1751-1754, 2000. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone rceptor B isoform. Proc Natl Acad Sci USA. 100: 9744-9749, 2003. Nieto A, Pena L, Perez-Alenza MD, Sanchez MA, Flores JM, Castano M. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol. 37: 239-247, 2000. Osterlund M, Kuiper GJM, Gustafsson JA, Hurd YL. Differential distribution and regulation of estrogen receptor-alpha and -beta mRNA within the female rat brain. Brain Res Mol Brain Res. 54: 175-180, 1998. Paech K, Webb P, Kuiper GG. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 277: 1508-1510, 1997. Paganini-Hill A, Dworsky R, Krauss RM. Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women. Am J Obstet Gynecol. 174: 897-902, 1996. Parodi AL, Misdorp W, Mialot JP, Mialot M, Hart AA, Hurtrel M, Salomon JC. Intratumoral BCG and Corynebacterium pavum therapy of canine mammary tumours before radical mastectomy. Cancer Immunol Immunother. 15: 172-177, 1983. Parodi AL, Mialot JP, Martin PM, Cotard M, Raynaud JP. Canine and feline mammary cancers as animal models for hormone-dependent human breast tumors: relationships between steroid receptor profiles and survival rates. Progr Cancer Res Ther. 31: 357-365, 1984. Perez Alenza MD, Pena L, Nieto AI, Castano M. Clinical and pathological prognostic factors in canine mammary tumors. Ann Ist Super Sanita. 33: 581-585, 1997. Perez Alenza MD, Rutteman GR, Pena L, Beynen AC, Cuesta P. Relation between habitual diet and canine mammary tumors in a case-control study. J Vet Intern Med. 12: 132-139, 1998. Perez Alenza MD, Pena L, del Castillo N, Nieto AI. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract. 4: 287-291, 2000. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Botstein D. Molecular portraits of human breast tumours. Nature. 406: 747-752, 2000. Petrovic B, Kocic B, Filipovic S, Rancic N, Filipovic A. Epidemiology of breast cancer in the city of Nis, Serbia. J BUON. 8: 147-150, 2003. Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B. Prognostic value of steroid receptors after long term follow-up of 2257 operable breast cancers. Br J Cancer. 73: 1545-1551, 1996. Ramos-Vara JA. Technical aspects of immunochemistry. Vet Pathol. 42: 405-426,2005. Romieux G, Maudelonde T, Ulmann A. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer. 74: 455-459, 1987. Rutteman GR, Willekes-Koolschijn N, Bevers MM, Van der Gugten AA, Misdorp W. Prolactin binding in benign and malignant mammary tissue of female dogs. Anticancer Res. 6: 829-835, 1986. Rutteman GR, Withrow SJ, MacEwen EG: Tumors of the mammary gland. In: Withrow SJ, MacEwen EG eds. Small animal clinical oncology, 3rd ed. WB Saunders Co, Philadelphia, 455-477, 2001. Rutteman GR, Cornelisse CJ, Dijkshoorn NJ, Poortman J, Misdorp W. Flow cytometric analysis of DNA ploidy in canine mammary tumors. Cancer Res. 48: 3411-3417, 1988. Rutteman GR, Misdorp W, Blankenstein MA, Van den Brom WE. Oestrogen (ER) and progestin (PR) in mammary tissue of the female dog: Different receptor profile in non-malignant and malignant states. Br J Cancer. 58: 594-599, 1988. Rutteman GR, Foekens JA, Blankenstein MA, Vos JH, Misdorp W. EGF-receptors in non-affected and tumorous dog mammary tussues. Eur J Cancer. 26: 182-186, 1990. Rutteman GR. Contraceptive steroids and the mammary gland: Is there a hazard? Breast Cancer Res Treat. 23: 29-41, 1992. Querzoli P, Ferretti S, Marzola A, Tassinari D, Indelli M, Marchetti E. Clinical usefulness of estrogen receptor immunocytochemistry in human breast cancer. Tumori. 78:287-290, 1992. Sartin EA, Barnes S, Kwapien RP, Wolfe LG. Estrogen and progesterone receptor status of mammary carcinomas and correlation with clinical outcome in dogs. Am J Vet Res. 53: 2196-2200, 1992. Sartin EA, Barnes S, Toivio-Kinnucan M, Wright JC, Wolfe LG. Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and sensitivity to tamoxifen and doxorubicin. Anticancer Res. 13: 229-236, 1993. Selman PJ, Mol JA, Rutteman GR, van Garderen E, Rijnberk A. Progestin-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology. 134: 287-292, 1994. Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst. 43: 1249-1261, 1969. Sorenmo KU, Shofer FS, Goldschmidt MH. Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J Vet Intern Med. 14 : 266-270, 2000. Sorenmo KU. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract. 33: 573-596, 2003. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matse JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98: 10869-10874, 2001 Stierer M, Rosen H, Weber R, Hanak H, Auerbach L, Spona J. A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Treat. 36: 11-21, 1995. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol. 24: 145-155, 2000. Thorpe SM, Rose C. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology. Cancer Surv. 5: 505-525, 1986. Tomlinson IPM, Nicolai H, Solomon E, Bodmer WF. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J Pathol. 180: 38-43, 1996. van Landeghem AAJ, Poortman J, Abuurs M, Thijssen JHH. Endogenous concentration and subcellular distribution of estrogen in normal and malignant human breast tissue. Cancer Res. 45: 2990-2906, 1985. Veldhoen N, Watterson J, Brash M, Milner J. Identification of tumor-assciated and germ line p53 mutations in canine mammary cancer. Br J Cancer. 81: 409-415, 1999. Vermeirsch H, Van Den Broeck W, Coryn M, Simoens D. Immunolocalization of sex hormone receptors in the canine uterine tube and their relation to sex steroid hormone concentrations. Reprod Fertil Dev. 14: 241-250, 2002. Walker B, Figgs LW, Zahm SH. Differences in cancer incidence, mortality, and survival between African Americans and whites. Environ Health Perspect. 8: 275-281, 1995. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat. 28: 9-20 ,1993. Yamagami T, Kobayashi T, Takahashi K, Sugiyama M. Influence of ovariectomy at the time of mastectomy on the prognosis for canine malignant mammary tumours. J Small Anim Pract. 37: 462-464, 1996. Yamagami T, Kobayashi T, Takahashi K, Sugiyama M. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. J Vet Med Sci. 58: 1079-1083, 1996. Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer. 13: 74-83, 2006. Yuzbasiyan-Gurkan V, Cao Y, Venta P, Yamini B. Loss of heterogenozygosity at the BRCA1 locus in canine mammary carcinoma. Proc Vet Cancer Soc. 19: 7, 1999.
摘要: 
內分泌透過分佈於母犬乳腺的受器在乳腺腫瘤的形成過程扮演很重要的角色 (Misdorp et al., 1988; Gustafsson et al., 1999)。已知動情素受器 (estrogen receptor-α, -β, ER-α,-β) 及黃體助孕素受器 (progesterone receptor, PR) 的表現與其他已被確認的預後因子,如腫瘤大小,組織學分級等有相關性。因此,本實驗以免疫組織化學研究113隻罹患乳腺腫瘤的母犬,包括89個惡性腫瘤及24個良性腫瘤病例,其腫瘤中ER-α、ER-β及PR的表現情形。結果顯示,ER-α,-β及PR在腫瘤中的陽性率分別為60.2 %、95.6 %和77.9%。這些陽性病例中,ER-α (p<0.05) 及PR(p<0.05)在良性腫瘤中的陽性率 (95.8 %,100 %) 顯著高於惡性腫瘤中的陽性率 (50.6 %, 71.9 %)。ER-α和PR的陽性率在直徑小於5公分、臨床分期為前三期及沒有淋巴結或遠端轉移的病犬腫瘤也明顯較高 (p<0.05)。PR的陽性率並隨著腫瘤中管腔形成的增加 (p<0.05) 及有絲分裂指數降低 (p<0.05) 而增加。然而,經過術後一年的追蹤,這三個內分泌受器中只有PR與術後存活時間有顯著相關。本實驗也發現惡性腫瘤ER-α陽性而PR為陰性的病犬,其存活率會明顯較ER-α和PR皆為陽性的病犬低 (p<0.05)。另一方面,病理學特徵如腫瘤大小超過5公分、臨床分期第四或第五期、淋巴結轉移或已遠端已轉移 (p<0.05) 和病理學診斷為肉瘤的犬隻,其術後一年存活率均明顯降低 (p<0.05)。因此,本研究推測內分泌受器PR的表現與腫瘤大小、臨床分期、轉移情形、病理學分類等特徵在本研究中均可作為罹患惡性乳腺腫瘤之母犬的預後因子。

Ovarian hormones play a key role through their receptors in the development of mammary tumours in female dogs (Misdorp et al., 1988; Gustafsson et al., 1999). The presences of estrogen receptor-α, -β (ER-α, -β) and progesterone receptor (PR) are well associated with other recognized prognostic factors (Nieto et al., 2000; Martin de las Mulas et al., 2004, 2005). We study the prognostic value of the immunohistochemically determined ER-α, -β and PR in a series of 113 bitches with mammary tumors, including 24 benign and 89 malignant tumors. The results indicated that 60.2 %, 95.6 %, and 77.9% of mammary tumors with positive expression of ER-α, ER-β and PR, respectively. Of these, the presences of ER-α (p<0.05) and PR (p<0.05) were significantly more frequent in benign tumors (100 % and 95.8 %, respectively) than in malignant tumors (50.6 % and 56.6 %, respectively). Positivity of ER-α and PR was higher in tumors that less than 5 cm, clinical stage I, II or III (p<0.05), and without lymph nodes or distant metastasis. Positivity of PR was also higher in tumors that with more tubule formation or lower mitosis index. However, only PR was significantly associated to postoperative survival time (p<0.05). We also found that dogs with malignant tumors showing ER-α+PR- have shorter survival time than those with ER-α+PR+ tumors after surgical removal (p<0.05). On the other hand, bitches with tumors that less than 5 cm, with lymph nodes or distant metastasis, clinical stage IV or V, and sarcoma type diagnosis would have lower survival rates. Therefore, the expression of PR, tumor size, clinical stage, metastasis status and pathologic type were important index for prognosis in bitches with malignant mammary tumors in this study.
URI: http://hdl.handle.net/11455/13420
其他識別: U0005-2407200720392900
Appears in Collections:獸醫學系所

Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.